Raymond James Has Negative Forecast for TSE:MDP Q3 Earnings

Medexus Pharmaceuticals Inc. (TSE:MDP) – Raymond James decreased their Q3 2025 EPS estimates for shares of Medexus Pharmaceuticals in a report issued on Tuesday, January 7th. Raymond James analyst M. Freeman now expects that the company will post earnings of ($0.03) per share for the quarter, down from their prior estimate of $0.01. Raymond James currently has a “Strong-Buy” rating and a $4.00 target price on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Raymond James also issued estimates for Medexus Pharmaceuticals’ Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at $0.03 EPS and Q1 2026 earnings at $0.23 EPS.

Several other equities analysts have also commented on MDP. Leede Financial set a C$8.25 price objective on Medexus Pharmaceuticals and gave the company a “speculative buy” rating in a research report on Monday, September 30th. Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a report on Monday, December 23rd. Two investment analysts have rated the stock with a buy rating and four have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Strong Buy” and an average price target of C$5.25.

Medexus Pharmaceuticals Stock Performance

MDP stock opened at C$4.04 on Friday. The company has a market capitalization of C$99.10 million, a price-to-earnings ratio of 80.80 and a beta of 1.96. The business’s 50 day moving average price is C$2.77 and its two-hundred day moving average price is C$2.53. Medexus Pharmaceuticals has a fifty-two week low of C$1.47 and a fifty-two week high of C$4.24.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.